MedTrace Logo

Drug-drug Interaction Study With GLPG3667 and Midazolam in Healthy Subjects

NCT04736927 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2021-03-03

No results posted yet for this study

Summary

A study in healthy volunteers to look at the effect of the test medicine, GLPG3667, on how midazolam (MDZ) is taken up and eliminated by the body.

Conditions

  • Healthy

Interventions

DRUG

GLPG3667

From Day 3 to Day 8, GLPG3667 capsules q.d. orally in fed state.

DRUG

Midazolam

On Day 1 and Day 7 as liquid formulation, orally in fed state.

Sponsors & Collaborators

  • Galapagos NV

    lead INDUSTRY

Principal Investigators

  • Natalia Rueda-Rincon, MD · Galapagos NV

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-15
Primary Completion
2021-02-25
Completion
2021-02-25

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04736927 on ClinicalTrials.gov